BriaCell Begins Patient Enrollment for Bria-OTS™ in Advanced Metastatic Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 - BriaCell Therapeutics, a biotechnology firm specializing in advanced immunotherapies for cancer treatment, has initiated a new Phase 1/2 clinical trial to evaluate the safety and efficacy of their innovative treatment, Bria-OTS™. This personalized off-the-shelf immunotherapy will be tested both as a standalone therapy and in conjunction with the PD-1 inhibitor tislelizumab for patients with advanced metastatic breast cancer.

Dr. William V. Williams, President and CEO of BriaCell, described the trial as a critical advancement for the company. “Introducing Bria-OTS™ as our second novel therapeutic candidate into clinical trials is a significant milestone. Our personalized immunotherapy approach is expected to yield more potent and enduring responses, especially when combined with immune checkpoint inhibitors,” he stated. Dr. Williams also expressed gratitude to BriaCell's scientific and clinical teams for successfully navigating the rigorous processes of Institutional Review Board (IRB) approval, Clinical Trial Site Agreement (CTA), and FDA authorization for Investigational New Drug (IND) filings. He also acknowledged the support of investors and collaborators in advancing Bria-OTS™ towards clinical application.

Chief Medical Officer Dr. Giuseppe Del Priore emphasized the potential impact of the off-the-shelf treatment. "The rapid treatment capabilities of our therapy can be transformative for patients with advanced metastatic breast cancer. We anticipate that Bria-OTS™ will improve both the quality of life and the survival rates for these heavily pretreated patients, offering a combination of benefits that is rare in late-stage cancer care," he noted.

About Bria-OTS™ Platform

The Bria-OTS™ platform is underpinned by numerous US and international patents and has shown promising clinical data, particularly through Bria-IMT™, BriaCell’s lead candidate currently in a pivotal Phase 3 trial for advanced metastatic breast cancer. This platform aims to create personalized, off-the-shelf immunotherapies. While the initial focus is on metastatic breast cancer, similar therapies are being developed for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™).

The Bria-OTS™ platform has received a Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). An open IND application exists for Bria-OTS™ under the name Bria-BRES™ targeted at advanced metastatic breast cancer. Bria-BRES™ is also set to begin a bucket trial, which will explore multiple product candidates within a single study framework, extending to other cancer types.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies designed to significantly improve cancer treatment outcomes. Their research and development efforts are aimed at creating personalized therapies that can provide durable and potent responses against various forms of cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!